Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03647358
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact	Ravinder Grewal, MD
Phone	212-639-2872
Email	grewalr@mskcc.org
Status	Recruiting
Phase	Phase 1
Start date	August 21, 2018
Completion date	August 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02658513` - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Withdrawn	`NCT01707056` - The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma	N/A
Completed	`NCT00215605` - Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies	Phase 1
Completed	`NCT06439745` - More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
Terminated	`NCT04327999` - Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System	Phase 2
Completed	`NCT02194920` - Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function	N/A
Enrolling by invitation	`NCT06095362` - Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW	Phase 1
Not yet recruiting	`NCT05949424` - OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults	Phase 4
Active, not recruiting	`NCT02145143` - Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study	N/A
Terminated	`NCT01865838` - A Study Into the Effect of Seprafilm in Open Total Thyroidectomy	N/A
Recruiting	`NCT00749697` - Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases	N/A
Enrolling by invitation	`NCT04411290` - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Completed	`NCT01813136` - Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma	Phase 2
Recruiting	`NCT05668962` - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC	Phase 2
Active, not recruiting	`NCT02185560` - Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Completed	`NCT04462471` - Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers	Phase 1
Completed	`NCT01433809` - Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm	N/A
Recruiting	`NCT00929318` - Influence of Thyroid Hormones on the Woundhealing Process	N/A
Completed	`NCT05178186` - Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer	N/A
Completed	`NCT02773667` - Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine